Alpha-1 antitrypsin protein and gene therapies decrease autoimmunity and delay arthritis development in mouse model

Journal of Translational Medicine

Volumn 9, Issue , 2011, Pages

  Grimstein, Christian ^a   Choi, Young Kook ^a   Wasserfall, Clive H ^a   Satoh, Minoru ^a,b   Atkinson, Mark A ^a   Brantly, Mark L ^b   Campbell Thompson, Martha ^a   Song, Sihong ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; AUTOANTIBODY; B CELL ACTIVATING FACTOR; COLLAGEN ANTIBODY; COLLAGEN TYPE 1; COLLAGEN TYPE 2; COLLAGEN TYPE 2 ANTIBODY; PARVOVIRUS VECTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE ACTIVATION; CHRONIC ARTHRITIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; RHEUMATOID ARTHRITIS; T LYMPHOCYTE ACTIVATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS RECOMBINANT; ANIMAL; ARTHRITIS; B LYMPHOCYTE; CATTLE; CELL LINE; DBA MOUSE; DISEASE MODEL; GENE THERAPY; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; PATHOLOGY; T LYMPHOCYTE;

ALPHA 1-ANTITRYPSIN; ANIMALS; ARTHRITIS, EXPERIMENTAL; AUTOANTIBODIES; AUTOIMMUNITY; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; CATTLE; CELL LINE; COLLAGEN TYPE II; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE THERAPY; HUMANS; MALE; MICE; MICE, INBRED DBA; T-LYMPHOCYTES;

EID: 79951956405     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-21     Document Type: Article

References (49)

1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003, 423:356-361. 10.1038/nature01661, 12748655.
2. Edwards CJ, Cooper C. Early environmental factors and rheumatoid arthritis. Clin Exp Immunol 2006, 143:1-5. 10.1111/j.1365-2249.2005.02940.x, 1809562, 16367927.
3. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007, 7:429-442. 10.1038/nri2094, 17525752.
4. Muller-Ladner U, Pap T, Gay RE, Neidhart M, Gay S. Mechanisms of disease: the molecular and cellular basis of joint destruction in rheumatoid arthritis. Nat Clin Pract Rheumatol 2005, 1:102-110. 10.1038/ncprheum0047, 16932639.
5. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet 2007, 370:1861-1874. 10.1016/S0140-6736(07)60784-3, 17570481.
6. Groh V, Bruhl A, El-Gabalawy H, Nelson JL, Spies T. Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc Natl Acad Sci USA 2003, 100:9452-9457. 10.1073/pnas.1632807100, 170939, 12878725.
7. Boskovic G, Twining SS. Local control of alpha1-proteinase inhibitor levels: regulation of alpha1-proteinase inhibitor in the human cornea by growth factors and cytokines. Biochim Biophys Acta 1998, 1403:37-46. 10.1016/S0167-4889(98)00018-4, 9622589.
8. Geboes K, Ray MB, Rutgeerts P, Callea F, Desmet VJ, Vantrappen G. Morphological identification of alpha-I-antitrypsin in the human small intestine. Histopathology 1982, 6:55-60. 10.1111/j.1365-2559.1982.tb02701.x, 7035326.
9. Keppler D, Markert M, Carnal B, Berdoz J, Bamat J, Sordat B. Human colon carcinoma cells synthesize and secrete alpha 1-proteinase inhibitor. Biol Chem Hoppe Seyler 1996, 377:301-311.
10. Ray MB, Desmet VJ, Gepts W. alpha-1-Antitrypsin immunoreactivity in islet cells of adult human pancreas. Cell Tissue Res 1977, 185:63-68. 10.1007/BF00226668, 338161.
11. Macen JL, Upton C, Nation N, McFadden G. SERP1, a serine proteinase inhibitor encoded by myxoma virus, is a secreted glycoprotein that interferes with inflammation. Virology 1993, 195:348-363. 10.1006/viro.1993.1385, 8337817.
12. Adkison AM, Raptis SZ, Kelley DG, Pham CT. Dipeptidyl peptidase I activates neutrophil-derived serine proteases and regulates the development of acute experimental arthritis. J Clin Invest 2002, 109:363-371. 150852, 11827996.
13. Kakimoto K, Matsukawa A, Yoshinaga M, Nakamura H. Suppressive effect of a neutrophil elastase inhibitor on the development of collagen-induced arthritis. Cell Immunol 1995, 165:26-32. 10.1006/cimm.1995.1183, 7671322.
14. Dhami R, Gilks B, Xie C, Zay K, Wright JL, Churg A. Acute cigarette smoke-induced connective tissue breakdown is mediated by neutrophils and prevented by alpha1-antitrypsin. Am J Respir Cell Mol Biol 2000, 22:244-252.
15. Janciauskiene S, Larsson S, Larsson P, Virtala R, Jansson L, Stevens T. Inhibition of lipopolysaccharide-mediated human monocyte activation, in vitro, by alpha1-antitrypsin. Biochem Biophys Res Commun 2004, 321:592-600. 10.1016/j.bbrc.2004.06.123, 15358147.
16. Janciauskiene SM, Nita IM, Stevens T. Alpha1-antitrypsin, old dog, new tricks. Alpha1-antitrypsin exerts in vitro anti-inflammatory activity in human monocytes by elevating cAMP. J Biol Chem 2007, 282:8573-8582. 10.1074/jbc.M607976200, 17261591.
17. Nita I, Hollander C, Westin U, Janciauskiene SM. Prolastin, a pharmaceutical preparation of purified human alpha1-antitrypsin, blocks endotoxin-mediated cytokine release. Respir Res 2005, 6:12. 10.1186/1465-9921-6-12, 549028, 15683545.
18. Libert C, Van Molle W, Brouckaert P, Fiers W. alpha1-Antitrypsin inhibits the lethal response to TNF in mice. J Immunol 1996, 157:5126-5129.
19. Tilg H, Vannier E, Vachino G, Dinarello CA, Mier JW. Antiinflammatory properties of hepatic acute phase proteins: preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1 beta synthesis by human peripheral blood mononuclear cells. J Exp Med 1993, 178:1629-1636. 10.1084/jem.178.5.1629, 2191253, 7693853.
20. Daemen MA, Heemskerk VH, van't Veer C, Denecker G, Wolfs TG, Vandenabeele P, Buurman WA. Functional protection by acute phase proteins alpha(1)-acid glycoprotein and alpha(1)-antitrypsin against ischemia/reperfusion injury by preventing apoptosis and inflammation. Circulation 2000, 102:1420-1426.
21. Grimstein C, Choi YK, Satoh M, Lu Y, Wang X, Campbell-Thompson M, Song S. Combination of alpha-1 antitrypsin and doxycycline suppresses collagen-induced arthritis. J Gene Med 12:35-44. 10.1002/jgm.1409, 19866480.
22. Zaiss AK, Muruve DA. Immunity to adeno-associated virus vectors in animals and humans: a continued challenge. Gene Ther 2008, 15:808-816. 10.1038/gt.2008.54, 18385765.
23. Song S, Morgan M, Ellis T, Poirier A, Chesnut K, Wang J, Brantly M, Muzyczka N, Byrne BJ, Atkinson M, Flotte TR. Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. Proc Natl Acad Sci USA 1998, 95:14384-14388. 10.1073/pnas.95.24.14384, 24382, 9826709.
24. Flotte TR, Afione SA, Conrad C, McGrath SA, Solow R, Oka H, Zeitlin PL, Guggino WB, Carter BJ. Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Proc Natl Acad Sci USA 1993, 90:10613-10617. 10.1073/pnas.90.22.10613, 47827, 7504271.
25. Xu L, Daly T, Gao C, Flotte TR, Song S, Byrne BJ, Sands MS, Parker Ponder K. CMV-beta-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human factor × in mice. Hum Gene Ther 2001, 12:563-573. 10.1089/104303401300042500, 11268288.
26. Kaplitt MG, Leone P, Samulski RJ, Xiao X, Pfaff DW, O'Malley KL, During MJ. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet 1994, 8:148-154. 10.1038/ng1094-148, 7842013.
27. Flannery JG, Zolotukhin S, Vaquero MI, LaVail MM, Muzyczka N, Hauswirth WW. Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus. Proc Natl Acad Sci USA 1997, 94:6916-6921. 10.1073/pnas.94.13.6916, 21259, 9192666.
28. Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 2002, 99:11854-11859. 10.1073/pnas.182412299, 129358, 12192090.
29. Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther 2006, 14:316-327. 10.1016/j.ymthe.2006.05.009, 16824801.
30. Zhong L, Li B, Mah CS, Govindasamy L, Agbandje-McKenna M, Cooper M, Herzog RW, Zolotukhin I, Warrington KH, Weigel-Van Aken KA, et al. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci USA 2008, 105:7827-7832. 10.1073/pnas.0802866105, 2402387, 18511559.
31. McCarty DM, Monahan PE, Samulski RJ. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther 2001, 8:1248-1254. 10.1038/sj.gt.3301514, 11509958.
32. Song S, Goudy K, Campbell-Thompson M, Wasserfall C, Scott-Jorgensen M, Wang J, Tang Q, Crawford JM, Ellis TM, Atkinson MA, Flotte TR. Recombinant adeno-associated virus-mediated alpha-1 antitrypsin gene therapy prevents type I diabetes in NOD mice. Gene Ther 2004, 11:181-186. 10.1038/sj.gt.3302156, 14712302.
33. Lu Y, Tang M, Wasserfall C, Kou Z, Campbell-Thompson M, Gardemann T, Crawford J, Atkinson M, Song S. Alpha1-antitrypsin gene therapy modulates cellular immunity and efficiently prevents type 1 diabetes in nonobese diabetic mice. Hum Gene Ther 2006, 17:625-634. 10.1089/hum.2006.17.625, 16776571.
34. Lu Y, Song S. Distinct immune responses to transgene products from rAAV1 and rAAV8 vectors. Proc Natl Acad Sci USA 2009, 106:17158-17162. 10.1073/pnas.0909520106, 2761323, 19805176.
35. Kim SH, Kim S, Evans CH, Ghivizzani SC, Oligino T, Robbins PD. Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-4. J Immunol 2001, 166:3499-3505.
36. Seki N, Sudo Y, Yoshioka T, Sugihara S, Fujitsu T, Sakuma S, Ogawa T, Hamaoka T, Senoh H, Fujiwara H. Type II collagen-induced murine arthritis. I. Induction and perpetuation of arthritis require synergy between humoral and cell-mediated immunity. J Immunol 1988, 140:1477-1484.
37. Taylor PC, Plater-Zyberk C, Maini RN. The role of the B cells in the adoptive transfer of collagen-induced arthritis from DBA/1 (H-2q) to SCID (H-2d) mice. Eur J Immunol 1995, 25:763-769. 10.1002/eji.1830250321, 7705406.
38. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004, 350:2167-2179. 10.1056/NEJMra032906, 15152062.
39. Churg A, Dai J, Zay K, Karsan A, Hendricks R, Yee C, Martin R, MacKenzie R, Xie C, Zhang L, et al. Alpha-1-antitrypsin and a broad spectrum metalloprotease inhibitor, RS113456, have similar acute anti-inflammatory effects. Lab Invest 2001, 81:1119-1131.
40. Zhang M, Ko KH, Lam QL, Lo CK, Srivastava G, Zheng B, Lau YL, Lu L. Expression and function of TNF family member B cell-activating factor in the development of autoimmune arthritis. Int Immunol 2005, 17:1081-1092. 10.1093/intimm/dxh287, 16000326.
41. Wang H, Marsters SA, Baker T, Chan B, Lee WP, Fu L, Tumas D, Yan M, Dixit VM, Ashkenazi A, Grewal IS. TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. Nat Immunol 2001, 2:632-637. 10.1038/89782, 11429548.
42. Pers JO, Daridon C, Devauchelle V, Jousse S, Saraux A, Jamin C, Youinou P. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 2005, 1050:34-39. 10.1196/annals.1313.004, 16014518.
43. Milner JM, Patel A, Rowan AD. Emerging roles of serine proteinases in tissue turnover in arthritis. Arthritis Rheum 2008, 58:3644-3656. 10.1002/art.24046, 19035508.
44. Miyata J, Tani K, Sato K, Otsuka S, Urata T, Lkhagvaa B, Furukawa C, Sano N, Sone S. Cathepsin G: the significance in rheumatoid arthritis as a monocyte chemoattractant. Rheumatol Int 2007, 27:375-382. 10.1007/s00296-006-0210-8, 16977463.
45. Zhang B, Lu Y, Campbell-Thompson M, Spencer T, Wasserfall C, Atkinson M, Song S. Alpha1-antitrypsin protects beta-cells from apoptosis. Diabetes 2007, 56:1316-1323. 10.2337/db06-1273, 17360983.
46. Ma H, Lu Y, Li H, Campbell-Thompson M, Parker M, Wasserfall C, Haller M, Brantly M, Schatz D, Atkinson M, Song S. Intradermal alpha1-antitrypsin therapy avoids fatal anaphylaxis, prevents type 1 diabetes and reverses hyperglycaemia in the NOD mouse model of the disease. Diabetologia 53:2198-2204. 10.1007/s00125-010-1829-2, 20593162.
47. Lu Y, Parker M, Pileggi A, Zhang B, Choi YK, Molano RD, Wasserfall C, Ricordi C, Inverardi L, Brantly M, et al. Human alpha 1-antitrypsin therapy induces fatal anaphylaxis in non-obese diabetic mice. Clin Exp Immunol 2008, 154:15-21. 10.1111/j.1365-2249.2008.03721.x, 2561098, 18759852.
48. Vandenberghe LH, Wang L, Somanathan S, Zhi Y, Figueredo J, Calcedo R, Sanmiguel J, Desai RA, Chen CS, Johnston J, et al. Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid. Nat Med 2006, 12:967-971. 10.1038/nm1445, 16845388.
49. Xin KQ, Mizukami H, Urabe M, Toda Y, Shinoda K, Yoshida A, Oomura K, Kojima Y, Ichino M, Klinman D, et al. Induction of robust immune responses against human immunodeficiency virus is supported by the inherent tropism of adeno-associated virus type 5 for dendritic cells. J Virol 2006, 80:11899-11910. 10.1128/JVI.00890-06, 1676308, 17005662.